In conclusion, combined checkpoint and BTK inhibition by tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strategy for patients with RT.

In patients with chronic lymphocytic leukemia, Richter transformation (RT) reflects the development of an aggressive lymphoma that is associated with poor response to …

The combination therapy of tislelizumab plus zanubrutinib is effective and well-tolerated for patients with Richter’s transformation.

Conclusions Combined checkpoint and BTK inhibition by tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strategy for pts with RT. Responses are durable and …

Tislelizumab plus zanubrutinib is an effective and well-tolerated treatment strategy for patients with chronic lymphocytic leukemia (CLL) with Richter transformation, according to a study …